All In MedTech

FDA Clearance Tracker · P240035-S002

ETHIZIA Hemostatic Patch

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 25, 2026

Approved

Time to decision

178 days

Received Dec 29, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P240035-S002
Device name
ETHIZIA Hemostatic Patch
Applicant
ETHICON, Inc.
Applicant location
Raritan, NJ
Received
Dec 29, 2025
Decided
Jun 25, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P240035

Device type

Device class
Class III
Regulation
21 CFR 878.4490

Every decision under product code SGV

FDA's approval statement

As written in FDA's record.

approval for the ETHIZIA Hemostatic Patch for expanding the indications to include minimally invasive surgical procedures on the liver.

Source documents

Other decisions for ETHICON, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.